Randomized, Controlled Dietary Treatment Study of Pediatric NAFLD
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 4
- 主要终点
- Change in Percentage of Liver Fat Measured by Magnetic Resonance Imaging (MRI) in the Intervention Group Compared to Change in the Control Group
研究概览
简要总结
This is an investigator initiated study being conducted in equal numbers at two sites, University of California, San Diego (UC San Diego) and Emory University (EU). The purpose of this study is to understand the potential of a low sugar diet for the treatment of nonalcoholic fatty liver disease (NAFLD) in children. Forty boys with NAFLD will be randomly assigned to either an intervention group or a habitual diet control group. The intervention will be a low sugar diet for a period of 8 weeks. The effect of this dietary change will be assessed using advanced magnetic resonance imaging (MRI) testing to measure liver fat.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 11 Years 至 16 Years（Child）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Boys age 11-16 years inclusive.
- •Clinical history consistent with NAFLD.
- •Biopsy-proven NAFLD
- •MRI measured Liver Proton Density Fat Fraction ≥10%
- •alanine aminotransferase (ALT) ≥ 45 u/L
- •No evidence of any other liver disease by clinical history or histological evaluation.
- •Written informed consent from parent or legal guardian.
- •Written informed assent from the child or adolescent.
排除标准
- •Exclusions will not be based upon gender, race, or ethnicity. Participants with a current history of the following conditions or any other health issues that make it unsafe for them to participate in the opinion of the Investigators will be excluded from the study:
- •History of significant alcohol intake (Alcohol Use Disorders Identification Test [AUDIT]) or inability to quantify alcohol consumption
- •Chronic use (more than 2 consecutive weeks) of medications known to cause hepatic steatosis or steatohepatitis in the past year.
- •The use of other known hepatotoxins within 120 days of baseline
- •History of total parenteral nutrition (TPN) use in the year prior to screening
- •History of bariatric surgery or planning to undergo bariatric surgery during the study duration
- •Significant depression
- •Non-compensated liver disease with any one of the following hematologic, biochemical, and serological criteria on entry into protocol:
- •Hemoglobin < 10 g/dL
- •White blood cell < 3,500 cells/mm
- •Neutrophil count < 1,500 cells/mm3 of blood
- •Platelets < 130,000 cells/mm3 of blood
- •Direct bilirubin > 1.0 mg/dL
- •Total bilirubin > 3 mg/dL
- •Albumin < 3.2 g/dL
- •International normalized ratio (INR) > 1.4
- •Evidence of other chronic liver disease
- •Children who are currently enrolled in a clinical trial or who received an investigational study drug or a medication with the intent to treat NAFLD/NASH in the past 60 days
- •Contraindications to MRI, e.g. metal in the eyes, implanted electronic devices, aneurysm clips, pacemaker, cochlear implants
- •Unable to have or complete the MRI exam due to body weight exceeding scanner table limit or girth exceeding scanner bore diameter
- •Subjects who are not able or willing to comply with the protocol or have any other condition that would impede compliance or hinder completion of the study, in the opinion of the investigator
- •Families with > 5 individuals
- •Failure to give informed consent
结局指标
主要结局
Change in Percentage of Liver Fat Measured by Magnetic Resonance Imaging (MRI) in the Intervention Group Compared to Change in the Control Group
时间窗: Measurements done at baseline and week 8.
The principal objective of this randomized and controlled pilot study is to evaluate whether 8 weeks of a low added sugar diet (\<3%) in boys with NAFLD will change liver fat % measured by MRI.
次要结局
- Change in Alanine Aminotransferase (ALT) From Baseline to Week 8(Measurements done at baseline and week 8)
- Change in Aspartate Aminotransferase (AST) From Baseline to Week 8(Measurements doen at baseline and week 8)
- Change in Gamma-Glutamyl Transpeptidase (GGT) From Baseline to Week 8(Measurements done at baseline and week 8)
- Change in Insulin From Baseline to Week 8(Measurements done at baseline and week 8)
- Change in Homeostasis Model Assessment- Insulin Resistance (HOMA-IR) From Baseline to Week 8(Measurements done at baseline and week 8)
- Change in Triglycerides From Baseline to Week 8(Measurements done at baseline and week 8)
研究者
Jeffrey B. Schwimmer, MD
Professor of Pediatrics
University of California, San Diego